Objectives: To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents. Methods: The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus. Results: Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases. Conclusions: The consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases. Key points: • Liver-specific contrast agents are recommended in MRI of the liver. • The hepatobiliary phase improves the detection and characterization of hepatocellular lesions. • Liver-specific contrast agents can improve the detection of HCC.

Neri, E., Bali, M. A., Ba-Ssalamah, A., Boraschi, P., Brancatelli, G., Alves, F. C., Grazioli, L., Helmberger, T., Lee, J. M., Manfredi, R., Marti-Bonmati, L., Matos, C., Merkle, E. M., Op De Beeck, B., Schima, W., Skehan, S., Vilgrain, V., Zech, C., Bartolozzi, C., ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents, <<EUROPEAN RADIOLOGY>>, 2016; 26 (4): 921-931. [doi:10.1007/s00330-015-3900-3] [http://hdl.handle.net/10807/172296]

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents

Manfredi, Riccardo;
2016

Abstract

Objectives: To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents. Methods: The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus. Results: Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases. Conclusions: The consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases. Key points: • Liver-specific contrast agents are recommended in MRI of the liver. • The hepatobiliary phase improves the detection and characterization of hepatocellular lesions. • Liver-specific contrast agents can improve the detection of HCC.
2016
Inglese
Neri, E., Bali, M. A., Ba-Ssalamah, A., Boraschi, P., Brancatelli, G., Alves, F. C., Grazioli, L., Helmberger, T., Lee, J. M., Manfredi, R., Marti-Bonmati, L., Matos, C., Merkle, E. M., Op De Beeck, B., Schima, W., Skehan, S., Vilgrain, V., Zech, C., Bartolozzi, C., ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents, <<EUROPEAN RADIOLOGY>>, 2016; 26 (4): 921-931. [doi:10.1007/s00330-015-3900-3] [http://hdl.handle.net/10807/172296]
File in questo prodotto:
File Dimensione Formato  
172296OA.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 325.81 kB
Formato Unknown
325.81 kB Unknown Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/172296
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 117
  • ???jsp.display-item.citation.isi??? 113
social impact